Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Debt and Interest (Tables)

Debt and Interest (Tables)

3 Months Ended

Mar. 31, 2023

Debt and Interest

Schedule of Debt

Total debt consists of the following:


		March 31,			December 31,
($ in thousands)		2023			2022			Interest rate		Maturity

Oaktree Note		$	50,000		$	50,000		11.00	%	August - 2025
EWB Term Loan			20,000			20,000		10.20	%	January - 2026
Runway Note			31,050			31,050		13.77	%	April - 2027
Less: Discount on notes payable			(8,736)			(9,320)
Total notes payable		$	92,314		$	91,730

Schedule of partner company installment payments - licenses

The following tables show the details of partner company installment payments – licenses for the periods presented.


		March 31, 2023
($ in thousands)		Short-term			Long-term			Total
Partner company installment payments - licenses		$	2,563		$	1,437		$	4,000
Add (Less): imputed interest			(275)			13			(262)
Total partner company installment payments - licenses		$	2,288		$	1,450		$	3,738


		December 31, 2022
($ in thousands)		Short-term			Long-term			Total
Partner company installment payments - licenses		$	7,563		$	1,437		$	9,000
Less: imputed interest			(328)			(25)			(353)
Total partner company installment payments - licenses		$	7,235		$	1,412		$	8,647

Interest Expense for all Debt Arrangements


		Three Months Ended March 31,
		2023									2022
($ in thousands)		Interest			Fees			Total			Interest			Fees			Total
LOC Fees		$	75		$	—		$	75		$	15		$	—		$	15
Oaktree Note			1,390			424			1,814			1,375			356			1,731
Partner company convertible preferred shares			260			60			320			—			—			—
Partner company installment payments - licenses			91			—			91			203			—			203
Partner company notes payable			1,500			160			1,660			368			33			401
Other			4			332			336			—			—			—
Total Interest Expense and Financing Fee		$	3,320		$	976		$	4,296		$	1,961		$	389		$	2,350